StemCell Institute (7096) AI Stock Analysis

• Market Cap: ¥8.30B
• Dividend Yield: N/A
• Average Volume (3M): 28.64K
• Price to Earnings (P/E): 33.1
• Beta (1Y): 0.35
• Revenue Growth: 4.58%
• EPS Growth: -39.30%
• Country: JP
• Employees: 98
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 4.24
• Shares Outstanding: 10,246,600
• 10 Day Avg. Volume: 23,150
• 30 Day Avg. Volume: 28,640
• PEG Ratio: 1.47
• Price to Book (P/B): 5.29
• Price to Sales (P/S): 5.19
• P/FCF Ratio: -1.37K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: ¥909.00 ▲(12.08% Upside)

The overall stock score is primarily influenced by strong financial performance, despite concerns over cash flow management. Technical analysis indicates bearish momentum, which negatively impacts the score. The valuation suggests moderate overvaluation, further affecting the stock's attractiveness.

StemCell Institute Business Overview & Revenue Model

Company Description

StemCell Institute (7096) is a biotechnology company specializing in regenerative medicine and stem cell research. The company operates in the healthcare sector, focusing on developing innovative therapies aimed at treating various medical conditions through the use of stem cells. Its core products and services include stem cell therapies, research and development of regenerative medicine technologies, and collaborations with academic institutions and pharmaceutical companies to advance stem cell applications in clinical settings.

How the Company Makes Money

The company generates revenue through multiple streams, primarily from the sale of its stem cell therapy products and services. This includes charging healthcare providers and patients for stem cell treatments as well as licensing its proprietary technologies to other firms. Additionally, StemCell Institute engages in research partnerships with universities and pharmaceutical companies, which often involve grants and funding for collaborative projects. These partnerships can lead to shared revenue from any resulting products, enhancing the company's financial stability and growth potential. Furthermore, the company may also receive income from patent royalties related to its innovations in stem cell therapies.

StemCell Institute Financial Statement Overview

Summary

StemCell Institute exhibits strong revenue growth and profitability, supported by robust margins and a solid capital structure. However, the negative free cash flow warrants attention, indicating a need for better cash management.

Income Statement

StemCell Institute shows strong revenue growth with a 7.97% increase from the previous year. The gross profit margin is robust at 63.16%, and the net profit margin has improved to 14.40%, indicating efficient cost management and profitability. The EBIT and EBITDA margins of 15.62% and 25.94% respectively, reflect solid operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a low debt-to-equity ratio of 0.20, showcasing financial stability. The equity ratio of 35.02% suggests a strong capital structure. However, the return on equity is moderate at 14.68%, indicating potential for improved profitability.

Cash Flow

Operating cash flow to net income ratio is strong at 1.21, indicating good cash generation relative to net income. However, the free cash flow has turned negative, indicating potential challenges in cash management. The decrease in free cash flow from the previous year is a concern, suggesting a need for better capital expenditure management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.70B	2.68B	2.48B	2.09B	1.78B	1.41B
Gross Profit	1.68B	1.69B	1.58B	1.34B	1.11B	924.21M
EBITDA	502.73M	695.19M	534.00M	402.49M	309.47M	119.66M
Net Income	249.97M	385.80M	310.98M	198.03M	133.73M	62.37M
Balance Sheet
Total Assets	7.38B	7.50B	6.54B	5.81B	5.22B	3.96B
Cash, Cash Equivalents and Short-Term Investments	2.71B	3.20B	2.85B	3.32B	3.51B	2.74B
Total Debt	497.26M	518.96M	10.78M	6.89M	0.00	0.00
Total Liabilities	4.72B	4.87B	3.85B	3.51B	3.11B	2.64B
Stockholders Equity	2.66B	2.63B	2.69B	2.30B	2.10B	1.32B
Cash Flow
Free Cash Flow	0.00	-10.11M	132.97M	39.77M	264.81M	-164.34M
Operating Cash Flow	0.00	467.69M	334.63M	99.67M	469.29M	239.00M
Investing Cash Flow	0.00	-259.08M	-811.77M	-285.10M	404.17M	-520.26M
Financing Cash Flow	0.00	146.70M	-1.33M	-869.00K	644.37M	0.00

StemCell Institute Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 811.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7096, the sentiment is Negative. The current price of 811 is below the 20-day moving average (MA) of 846.20, below the 50-day MA of 903.78, and below the 200-day MA of 1124.16, indicating a bearish trend. The MACD of -32.40 indicates Positive momentum. The RSI at 30.68 is Neutral, neither overbought nor oversold. The STOCH value of 26.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7096.

StemCell Institute Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7096	61 Neutral	¥8.30B	33.05	―	―	4.58%	-39.30%
7774	58 Neutral	¥18.80B	―	―	―	-5.65%	-469.19%
4880	55 Neutral	¥10.13B	-202.30	―	1.01%	-13.81%	-107.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4978	49 Neutral	¥15.92B	―	―	―	13.83%	34.66%
4599	47 Neutral	¥16.96B	-8.77	―	―	―	5.58%
7776	46 Neutral	¥15.15B	-14.61	―	―	-22.81%	2.69%